Thermostable subunit vaccines for pulmonary delivery: How close are we?

Current Pharmaceutical Design

Volumn 22, Issue 17, 2016, Pages 2561-2576

  Foged, Camilla ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adjuvant; Drug delivery; Nanomedicine; Pulmonary administration; Thermostable; Vaccine

Indexed keywords

ANTIGEN; RECOMBINANT HUMAN INSULIN; SUBUNIT VACCINE;

CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DRY POWDER INHALER; EBOLA HEMORRHAGIC FEVER; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INNATE IMMUNITY; MUCOSAL IMMUNITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFRIGERATOR; REVIEW; TUBERCULOSIS; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; TEMPERATURE;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LUNG; TEMPERATURE; VACCINES, SUBUNIT;

EID: 84974712289     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160202141603     Document Type: Review

References (193)

1. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med 2014; 6: 708-20.
2. FastStats Homepage, Deaths and Mortality, National Center for Health Statistics [homepage on the Internet]. Centers for Disease Control and Prevention (CDC) [updated 2015 Sep 30; cited 2015 Oct 15]. Available from: (http: //www.cdc.gov/nchs/fastats/deaths.htm).
3. Tonnis WF, Kersten GF, Frijlink HW, Hinrichs WL, de Boer AH, Amorij JP. Pulmonary vaccine delivery: a realistic approach? J Aerosol Med Pulm Drug Deliv 2012; 25: 249-60.
4. Tonnis WF, Lexmond AJ, Frijlink HW, de Boer AH, Hinrichs WL. Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv 2013; 10: 1383-97.
5. Metzger RJ, Klein OD, Martin GR, Krasnow MA. The branching programme of mouse lung development. Nature 2008; 453: 745-50.
6. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
7. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56: 588-99.
8. Schlingmann B, Molina SA, Koval M. Claudins: Gatekeepers of lung epithelial function. Sem Cell Dev Biol 2015; 42: 47-57.
9. Steimer A, Haltner E, Lehr CM. Cell culture models of the respiratory tract relevant to pulmonary drug delivery. J Aerosol Med 2005; 18: 137-82.
10. Chilvers MA, O’Callaghan C. Local mucociliary defence mechanisms. Paed Resp Rev 2000; 1: 27-34.
11. Stannard W, O’Callaghan C. Ciliary function and the role of cilia in clearance. J Aerosol Med 2006; 19: 110-15.
12. Rogers DF. Physiology of Airway Mucus Secretion and Pathophysiology of Hypersecretion. Resp Care 2007; 52: 1134-49.
13. Rubin BK. Secretion properties, clearance, and therapy in airway disease. Trans Resp Med 2014; 2: 6.
14. Foster WM, Langenback E, Bergofsky EH. Measurement of tracheal and bronchial mucus velocities in man: relation to lung clearance. J Appl Physiol Respir Environ Exerc Physiol 1980; 48: 965-71.
15. Nicod LP. Pulmonary defence mechanisms. Respiration 1999; 66: 2-11.
16. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363: 2233-47.
17. Cone RA. Barrier properties of mucus. Adv Drug Delivery Rev 2009; 61: 75-85.
18. Whitsett JA, Alenghat T. Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat Immunol 2015; 16: 27-35.
19. Bur M, Lehr CM. Pulmonary cell culture models to study the safety and efficacy of innovative aerosol medicines. Expert Opin Drug Deliv 2008; 5: 641-52.
20. Lopez-Rodriguez E, Perez-Gil J. Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy. Biochim Biophys Acta 2014; 1838: 1568-85.
21. Larsen ST, Dallot C, Larsen SW, et al. Mechanism of action of lung damage caused by a nanofilm spray product. Toxicol Sci 2014; 140: 436-44.
22. Sato S, Kiyono H. The mucosal immune system of the respiratory tract. Curr Opin Virol 2012; 2: 225-32.
23. Werner JL, Steele C. Innate receptors and cellular defense against pulmonary infections. J Immunol 2014; 193: 3842-50.
24. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol 2007; 8: 11-3.
25. Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol 2011; 11: 221-30.
26. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
27. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
28. Seong SY, Matzinger P. Hydrophobicity: an ancient damageassociated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469-78.
29. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6: 148-58.
30. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004; 10: 927-34.
31. Halle S, Dujardin HC, Bakocevic N, et al. Induced bronchusassociated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med 2009; 206: 2593-601.
32. Tschernig T, Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 2000; 68: 1-8.
33. Bienenstock J, Befus D. Gut-and bronchus-associated lymphoid tissue. Am J Anat 1984; 170: 437-45.
34. Sminia T, van der Brugge-Gamelkoorn GJ, Jeurissen SH. Structure and function of bronchus-associated lymphoid tissue (BALT). Crit Rev Immunol 1989; 9: 119-50.
35. Luhrmann A, Tschernig T, Pabst R. Stimulation of bronchusassociated lymphoid tissue in rats by repeated inhalation of aerosolized lipopeptide MALP-2. Pathobiology 2002; 70: 266-9.
36. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez, et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat Immunol 2011; 12: 639-46.
37. Fleige H, Ravens S, Moschovakis GL, et al. IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med 2014; 211: 643-51.
38. Kumar P, Chen K, Kolls JK. Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol 2013; 25: 373-80.
39. Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 2012; 14: 17-46.
40. Schaefer L. Complexity of danger: The diverse nature of damageassociated molecular patterns. J Biol Chem 2014; 289: 35237-245.
41. Guilliams M, De Kleer I, Henri S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med 2013; 210: 1977-92.
42. Cai Y, Sugimoto C, Arainga M, Alvarez X, Didier ES, Kuroda MJ. In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: Implications for understanding lung disease in humans. J Immunol 2014; 192: 2821-2829.
43. Schneberger D, Aharonson-Raz K, Singh B. Monocyte and macrophage heterogeneity and Toll-like receptors in the lung. Cell Tissue Res 2011; 343: 97-106.
44. Barletta KE, Cagnina RE, Wallace KL, Ramos SI, Mehrad B, Linden J. Leukocyte compartments in the mouse lung: Distinguishing between marginated, interstitial, and alveolar cells in response to injury. J Immunol Methods 2012; 375: 100-10.
45. Guilliams M, Lambrecht BN, Hammad H. Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections. Mucosal Immunol 2013; 6: 464-73.
46. Landsman L, Jung S. Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages. J Immunol 2007; 179: 3488-94.
47. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009; 9: 153-61.
48. von Garnier C, Nicod LP. Immunology taught by lung dendritic cells. Swiss Med Wkly 2009; 139: 186-92.
49. Desch AN, Randolph GJ, Murphy K, et al. CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cellassociated antigen. J Exp Med 2011; 208: 1789-97.
50. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009; 10: 1237-44.
51. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. CCR2+ Monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 2008; 180: 2562-72.
52. Sung SS, Fu SM, Rose CE, Gaskin F, Ju ST, Beaty SR. A major lung CD103 (Alpha-E) Beta-7 integrin-positive epithelial dendritic cell population expressing langerin and tight junction proteins. J Immunol 2006; 176: 2161-72.
53. Randall TD. Bronchus-Associated Lymphoid Tissue (BALT): Structure and Function. In: Fagarasan S, Cerutti A, Eds. Advances in Immunology Mucosal Immunity. USA: Academic Press 2010; pp. 187-241.
54. Mora JR, Iwata M, Eksteen B, et al. Generation of Gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006; 314: 1157-60.
55. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 2011; 29: 273-93.
56. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol 2008; 8: 421-34.
57. Brandtzaeg P. Secretory IgA (SIgA): designed for antimicrobial defence. Front Immunol 2013; 4: 1-17.
58. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol 2012; 12: 821-832.
59. Brandtzaeg P. Mucosal Immunity: Induction, Dissemination, and Effector Functions. Scand J Immunol 2009; 70: 505-15.
60. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012; 12: 592-605.
61. Renegar KB, Small PA, Jr., Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004; 173: 1978-86.
62. Walsh EE, Peterson DR, Falsey AR. Risk Factors for Severe Respiratory Syncytial Virus Infection in Elderly Persons. J Infect Dis 2004; 189: 233-8.
63. Onodera T, Takahashi Y, Yokoi Y, et al. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc Natl Acad Sci USA 2012; 109: 2485-90.
64. Meyer M, Garron T, Lubaki NM, et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest 2015; 125: 3241-55.
65. Lawrence CW, Braciale TJ. Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol 2004; 173: 1209-18.
66. Yoon H, Legge KL, Sung SS, Braciale TJ. Sequential activation of CD8+ T cells in the draining lymph nodes in response to pulmonary virus infection. J Immunol 2007; 179: 391-9.
67. Khanna KM, Aguila CC, Redman JM, Suarez-Ramirez JE, Lefrancois L, Cauley LS. In situ imaging reveals different responses by naive and memory CD8 T cells to late antigen presentation by lymph node DC after influenza virus infection. Eur J Immunol 2008; 38: 3304-15.
68. Kim TS, Hufford MM, Sun J, Fu YX, Braciale TJ. Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med 2010; 207: 1161-72.
69. Kim TS, Braciale TJ. Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8+ T cell responses. PLoS One 2009; 4: e4204.
70. GeurtsvanKessel CH, Willart MA, van Rijt LS, et al. Clearance of influenza virus from the lung depends on migratory langerin+CD11b-but not plasmacytoid dendritic cells. J Exp Med 2008; 205: 1621-34.
71. Belz GT, Smith CM, Kleinert L, et al. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc Natl Acad Sci USA 2004; 101: 8670-75.
72. Moltedo B, Li W, Yount JS, Moran TM. Unique type I interferon responses determine the functional fate of migratory lung dendritic cells during influenza virus infection. PLoS Pathog 2011; 7: e1002345.
73. Lawrence CW, Ream RM, Braciale TJ. Frequency, Specificity, and Sites of Expansion of CD8+ T Cells during Primary Pulmonary Influenza Virus Infection. J Immunol 2005; 174: 5332-40.
74. McGill J, Legge KL. Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J Immunol 2009; 183: 4177-81.
75. Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nat Rev Immunol 2012; 12: 295-305.
76. Topham DJ, Tripp RA, Doherty PC. CD8(+) T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997; 159: 5197-200.
77. Hufford MM, Kim TS, Sun J, Braciale TJ. Antiviral CD8(+) T cell effector activities in situ are regulated by target cell type. J Exp Med 2011; 208: 167-80.
78. Le FA, Jalil A, Vergnon I, et al. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 2007; 204: 559-70.
79. Woodberry T, Suscovich TJ, Henry LM, et al. Alpha E beta 7 (CD103) expression identifies a highly active, tonsil-resident effector-memory CTL population. J Immunol 2005; 175: 4355-62.
80. Herold S, Steinmueller M, von Wulffen W, et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophageexpressed TNF-related apoptosis-inducing ligand. J Exp Med 2008; 205: 3065-77.
81. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009; 15: 277-84.
82. Yun Y, Srinivas G, Kuenzel S, et al. Environmentally determined differences in the murine lung microbiota and their relation to alveolar architecture. PLoS One 2014; 9: e113466.
83. Charlson ES, Bittinger K, Haas AR, et al. Topographical Continuity of Bacterial Populations in the Healthy Human Respiratory Tract. Am J Respir Crit Care Med 2011; 184: 957-63.
84. Barfod KK, Roggenbuck M, Hansen LH, et al. The murine lung microbiome in relation to the intestinal and vaginal bacterial communities. BMC Microbiol 2013; 13: 303.
85. Pezzulo AA, Kelly PH, Nassar BS, et al. Abundant DNase Isensitive bacterial DNA in healthy porcine lungs and its implications for the lung microbiome. Appl Environ Microbiol 2013; 79: 5936-41.
86. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011; 6: e16384.
87. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1073-80.
88. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-20.
89. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012; 336: 1268-73.
90. The Human Microbiome Jumpstart Reference Strains Consortium. A catalog of reference genomes from the human microbiome. Science 2010; 328: 994-9.
91. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-10.
92. Bazin H. A brief history of the prevention of infectious diseases by immunisations. Comp Immunol Microbiol Infect Dis 2003; 26: 293-308.
93. Moore ZS, Seward JF, Lane JM. Smallpox. Lancet 2004; 367: 425-35.
94. Brimnes N. Variolation, vaccination and popular resistance in early colonial south India. Med Hist 2004; 48: 199-228.
95. Dinc G, Ulman YI. The introduction of variolation 'A La Turca' to the West by Lady Mary Montagu and Turkey's contribution to this. Vaccine 2007; 25: 4261-5.
96. Stewart AJ, Devlin PM. The history of the smallpox vaccine. J Infect 2006; 52: 329-34.
97. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 2007; 25: 1361-6.
98. Foged C. Subunit vaccines of the future: The need for safe, customized and optimized particulate delivery systems. Ther Deliv 2011; 2: 1057-77.
99. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3: 445-50.
100. Brito LA, O’Hagan DT. Designing and building the next generation of improved vaccine adjuvants. J Control Release 2014; 190: 563-79.
101. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54 Pt 1: 1-13.
102. O'Hagan DT, Fox CB. New generation adjuvants-From empiricism to rational design. Vaccine 2015; 33 (Suppl 2): B14-B20.
103. Lindblad EB. Aluminum Adjuvants: Basic Concepts and Progress in Understanding. In: Foged C, Rades T, Perrie Y, Hook S, Eds. Subunit Vaccine Delivery. New York: Springer Science+Business Media 2015; pp. 33-57.
104. Shah RR, Brito LA, O’Hagan DT, Amiji M. Emulsions as Vaccine Adjuvants. In: Foged C, Rades T, Perrie Y, Hook S, Eds. Subunit Vaccine Delivery. New York: Springer Science+Business Media 2015; pp. 59-76.
105. Kastner E, Schmidt ST, Wilkinson A, Christensen D, Perrie Y. The Application of Liposomes as Vaccine Adjuvants. In: Foged C, Rades T, Perrie Y, Hook S, Eds. Subunit Vaccine Delivery. New York: Springer Science+Business Media 2015; pp. 77-94.
106. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: Unraveling a century old mystery. Eur J Immunol 2008; 38: 2068-71.
107. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27: 3331-4.
108. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
109. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.
110. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-7.
111. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5: 505-17.
112. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19: 1597-608.
113. Fraser CK, Diener KR, Brown MP, Hayball JD. Improving vaccines by incorporating immunological coadjuvants. Expert Rev Vaccines 2007; 6: 559-78.
114. Liang MT, Davies NM, Blanchfield JT, Toth I. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv 2006; 3: 379-88.
115. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008; 364: 272-80.
116. Hamborg M, Foged C. Characterizing the Association Between Antigens and Adjuvants. In: Foged C, Rades T, Perrie Y, Hook S, Eds. Subunit Vaccine Delivery. New York: Springer Science+Business Media 2015; pp. 413-26.
117. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010; 9: 1095-107.
118. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005; 298: 315-22.
119. Hamborg M, Jorgensen L, Bojsen AR, Christensen D, Foged C. Protein antigen adsorption to the DDA/TDB liposomal adjuvant: effect on protein structure, stability, and liposome physicochemical characteristics. Pharm Res 2013; 30: 140-55.
120. Hamborg M, Kramer R, Schante CE, et al. The physical stability of the recombinant tuberculosis fusion antigens h1 and h56. J Pharm Sci 2013; 102: 3567-78.
121. Hamborg M, Rose F, Jorgensen L, et al. Elucidating the mechanisms of protein antigen adsorption to the CAF/NAF liposomal vaccine adjuvant systems: effect of charge, fluidity and antigen-to-lipid ratio. Biochim Biophys Acta 2014; 1838: 2001-10.
122. Davidsen J, Rosenkrands I, Christensen D, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718: 22-31.
123. Agger EM, Rosenkrands I, Hansen J, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008; 3: e3116.
124. Geisel RE, Sakamoto K, Russell DG, Rhoades ER. In vivo activity of released cell wall lipids of mycobacterium bovis bacillus calmette-guerin is due principally to trehalose mycolates. J Immunol 2005; 174: 5007-15.
125. Schoenen H, Bodendorfer B, Hitchens K, et al. Cutting Edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalosedibehenate. J Immunol 2010; 184: 2756-60.
126. Nordly P, Agger EM, Andersen P, Nielsen HM, Foged C. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: Physico-chemical characterization and induction of CD8(+) T-cell responses in vivo. Pharm Res 2011; 28: 553-62.
127. Nordly P, Rose F, Christensen D, et al. Immunity by formulation design: Induction of high CD8(+) T-cell responses by poly(I: C) incorporated into the CAF01 adjuvant via a double emulsion method. J Controlled Release 2011; 150: 307-17.
128. Nordly P, Korsholm KS, Pedersen EA, et al. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo. Eur J Pharm Biopharm 2011; 77: 89-98.
129. Korsholm KS, Hansen J, Karlsen K, et al. Induction of CD8+ Tcell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. Vaccine 2014; 32: 3927-35.
130. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol 2009; 27: 26-34.
131. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res 2008; 25: 781-91.
132. Rose F, Wern JE, Ingvarsson PT, et al. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A qualityby-design approach. J Control Release 2015; 210: 48-57.
133. Ingvarsson PT, Yang M, Mulvad H, Nielsen HM, Rantanen J, Foged C. Engineering of an inhalable DDA/TDB liposomal adjuvant: a quality-by-design approach towards optimization of the spray drying process. Pharm Res 2013; 30: 2772-84.
134. Dey AK, Malyala P, Singh M. Physicochemical and functional characterization of vaccine antigens and adjuvants. Expert Rev Vaccines 2014; 13: 671-85.
135. Balu S, Reljic R, Lewis MJ, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011; 186: 3113-9.
136. Hafner LM, Wilson DP, Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 2014; 32: 1563-71.
137. Brunham RC, Rappuoli R. Chlamydia trachomatis control requires a vaccine. Vaccine 2013; 31: 1892-7.
138. Johri AK, Paoletti LC, Glaser P, et al. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 2006; 4: 932-42.
139. Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Global tuberculosis control: Lessons learnt and future prospects. Nat Rev Microbiol 2012; 10: 407-16.
140. Kunkel EJ, Kim CH, Lazarus NH, et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest 2003; 111: 1001-10.
141. Cha HR, Ko HJ, Kim ED, et al. Mucosa-Associated Epithelial Chemokine/CCL28 Expression in the Uterus Attracts CCR10+ IgA Plasma Cells following Mucosal Vaccination via Estrogen Control. J Immunol 2011; 187: 3044-52.
142. Nogueira CV, Zhang X, Giovannone N, Sennott EL, Starnbach MN. Protective Immunity against Chlamydia trachomatis Can Engage Both CD4+ and CD8+ T Cells and Bridge the Respiratory and Genital Mucosae. J Immunol 2015; 194: 2319-29.
143. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45-53.
144. Holmgren J, Svennerholm AM. Vaccines against mucosal infections. Curr Opin Immunol 2012; 24: 343-53.
145. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005; 5: 149-61.
146. Olsen AW, Follmann F, Erneholm K, Rosenkrands I, Andersen P. Protection against chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. J Infect Dis 2015; 212(6): 978-89.
147. de Souza Carvalho C, Daum N, Lehr CM. Carrier interactions with the biological barriers of the lung: Advanced in vitro models and challenges for pulmonary drug delivery. Adv Drug Deliv Rev 2014; 75: 129-40.
148. Blank F, Stumbles P, von Garnier C. Opportunities and challenges of the pulmonary route for vaccination. Expert Opin Drug Deliv 2011; 8: 547-63.
149. Todoroff J, Lemaire MM, Fillee C, et al. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PLoS One 2013; 8: e63344.
150. Blank F, Stumbles PA, Seydoux E, et al. Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes. Am J Respir Cell Mol Biol 2013; 49: 67-77.
151. Carter N, Curran M. Live Attenuated Influenza Vaccine (FluMist®; FluenzTM). Drugs 2011; 71: 1591-622.
152. Murugappan S, Frijlink HW, Petrovsky N, Hinrichs WLJ. Enhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant. Eur J Pharm Sci 2015; 66: 118-22.
153. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021-8.
154. Bishai W, Sullivan Z, Bloom BR, Andersen P. Bettering BCG: a tough task for a TB vaccine? Nat Med 2013; 19: 410-1.
155. Hokey DA, Wachholder R, Darrah PA, et al. A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine. Hum Vaccin Immunother 2014; 10: 2199-210.
156. White AD, Sibley L, Dennis MJ, et al. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin Vaccine Immunol 2013; 20: 663-72.
157. Ebola (Ebola Virus Disease), Outbreaks, Outbreak Chronology [homepage on the Internet]. Centers for Disease Control and Prevention (CDC) [updated 2015 Oct 13; cited 2015 Oct 15]. Available from: http: //www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html.
158. Ebola (Ebola Virus Disease), 2014 Ebola Outbreak in West Africa-Case Counts [homepage on the Internet]. Centers for Disease Control and Prevention (CDC) [updated 2015 Oct 13; cited 2015 Oct 15]. Available from: http: //www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/casecounts. html.
159. Jaax N, Jahrling P, Geisbert T, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995; 346: 1669-71.
160. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, Jahrling PB. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120: 140-55.
161. Wong G, Qiu X, Richardson JS, et al. Ebola virus transmission in guinea pigs. J Virol 2015; 89: 1314-1323.
162. Osterholm MT, Moore KA, Kelley NS, et al. Transmission of Ebola viruses: what we know and what we do not know. MBio 2015; 6: e00137.
163. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986; 75: 433-8.
164. Bloom DE, Canning D, Weston M. The value of vaccination. World Econ 2005; 6: 15-39.
165. Wanning S, Süverkrüp R, Lamprecht A. Pharmaceutical spray freeze drying. Int J Pharm 2015; 488: 136-53.
166. Tonnis WF, Amorij JP, Vreeman MA, Frijlink HW, Kersten GF, Hinrichs WL. Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars. Eur J Pharm Sci 2014; 55: 36-45.
167. Morello M, Krone CL, Dickerson S, et al. Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies. Tuberculosis 2009; 89: 371-7.
168. Seville PC, Li HY, Learoyd TP. Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst 2007; 24: 307-60.
169. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008; 25: 999-1022.
170. Ingvarsson PT, Yang M, Nielsen HM, Rantanen J, Foged C. Stabilization of liposomes during drying. Expert Opin Drug Deliv 2011; 8: 375-88.
171. Crowe JH, Hoekstra FA, Crowe LM. Anhydrobiosis. Ann Rev Physiol 1992; 54: 579-99.
172. Crowe JH, Carpenter JF, Crowe LM. The role of vitrification in anhydrobiosis. Ann Rev Physiol 1998; 60: 73-103.
173. Serdakowski AL, Dordick JS. Enzyme activation for organic solvents made easy. Trends Biotechnol 2008; 26: 48-54.
174. Ingvarsson PT, Schmidt ST, Christensen D, et al. Designing CAFadjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01. J Control Release 2013; 167: 256-64.
175. Saluja V, Amorij JP, Kapteyn JC, de Boer AH, Frijlink HW, Hinrichs WLJ. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release 2010; 144: 127-33.
176. Hoppentocht M, Hoste C, Hagedoorn P, Frijlink HW, de Boer AH. In vitro evaluation of the DP-4M PennCentury™ insufflator. Eur J Pharm Biopharm 2014; 88: 153-9.
177. Tonnis WF, Bagerman M, Weij M, et al. A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals. Eur J Pharm Biopharm 2014; 88: 1056-63.
178. Berkenfeld K, Lamprecht A, McConville J. Devices for dry powder drug delivery to the lung. AAPS PharmSciTech 2015; 16: 479-90.
179. Frijlink HW, de Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004; 1: 67-86.
180. de Boer AH, Chan HK, Price R. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? Adv Drug Deliv Rev 2012; 64: 257-74.
181. Grasmeijer F, Lexmond AJ, van den Noort M, Hagedoorn P, Hickey AJ, Frijlink HW, de Boer AH. New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation. PLoS One 2014; 9: e87825.
182. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing. J Aerosol Med 1993; 6: 99-110.
183. Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med 2006; 19: 456-65.
184. Lexmond AJ, Kruizinga TJ, Hagedoorn P, Rottier BL, Frijlink HW, de Boer AH. Effect of inhaler design variables on paediatric use of dry powder inhalers. PLoS One 2014; 9: e99304.
185. de Boer AH, Hagedoorn P. The role of disposable inhalers in pulmonary drug delivery. Expert Opin Drug Deliv 2014; 12: 143-57.
186. Agarkhedkar S, Kulkarni PS, Winston S, et al. Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial. Vaccine 2014; 32: 6791-7.
187. Cape S, Villa J, Huang E, Yang TH, Carpenter J, Sievers R. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 2008; 25: 1967-990.
188. Lin WH, Griffin DE, Rota PA, et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci USA 2011; 108: 2987-92.
189. Kling J. Dreamboat sinks prospects for fast approval of inhaled insulin. Nat Biotechnol 2011; 29: 175-6.
190. Kling J. Inhaled insulin's last gasp? Nat Biotechnol 2008; 26: 479-80.
191. Kaur N, Zhou B, Breitbeil F, et al. A delineation of diketopiperazine self-assembly processes: understanding the molecular events involved in Nepsilon-(fumaroyl)diketopiperazine of L-Lys (FDKP) interactions. Mol Pharm 2008; 5: 294-315.
192. Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P. Technosphere® Insulin: Defining the Role of Technosphere Particles at the Cellular Level. J Diabetes Sci Technol 2009; 3: 545-54.
193. de Boer AH, Hagedoorn P, Westerman EM, Le Brun PP, Heijerman HG, Frijlink HW. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Eur J Pharm Sci 2006; 28: 171-8.